[go: up one dir, main page]

AR015966A1 - USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT - Google Patents

USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT

Info

Publication number
AR015966A1
AR015966A1 ARP980105131A ARP980105131A AR015966A1 AR 015966 A1 AR015966 A1 AR 015966A1 AR P980105131 A ARP980105131 A AR P980105131A AR P980105131 A ARP980105131 A AR P980105131A AR 015966 A1 AR015966 A1 AR 015966A1
Authority
AR
Argentina
Prior art keywords
preparation
pde4 inhibitor
treatment
prurite
inhibitor compound
Prior art date
Application number
ARP980105131A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR015966A1 publication Critical patent/AR015966A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Uso de un compuesto inhibidor de PDE4 (fosfodiesterasa 4) para la preparacion de un medicamento util para el tratamiento de prurito en un mamífero quenecesita de ello, que comprende una cantidad eficaz de un compuesto de un inhibidor de PDE4, distinto de CP 80633. Dicho compuesto se utiliza en la profilaxiso terapia de enfermedades o trastornos que tienen un componente prurítico.Use of a PDE4 inhibitor compound (phosphodiesterase 4) for the preparation of a medicament useful for the treatment of pruritus in a mammal in need thereof, comprising an effective amount of a compound of a PDE4 inhibitor, other than CP 80633. Said Compound is used in the prophylaxis therapy of diseases or disorders that have a pruritic component.

ARP980105131A 1997-10-17 1998-10-15 USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT AR015966A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6374697P 1997-10-17 1997-10-17

Publications (1)

Publication Number Publication Date
AR015966A1 true AR015966A1 (en) 2001-05-30

Family

ID=22051225

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105131A AR015966A1 (en) 1997-10-17 1998-10-15 USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT

Country Status (18)

Country Link
EP (1) EP1030666A4 (en)
JP (1) JP2001520196A (en)
KR (1) KR20010031149A (en)
CN (1) CN1306426A (en)
AR (1) AR015966A1 (en)
AU (1) AU740875B2 (en)
BR (1) BR9814080A (en)
CA (1) CA2306985A1 (en)
CO (1) CO4810374A1 (en)
CZ (1) CZ20001376A3 (en)
HU (1) HUP0003792A3 (en)
IL (1) IL135581A0 (en)
NO (1) NO20001847D0 (en)
NZ (1) NZ503551A (en)
PL (1) PL341062A1 (en)
TR (1) TR200001040T2 (en)
WO (1) WO1999020280A1 (en)
ZA (1) ZA989450B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ526531A (en) 2001-01-31 2005-02-25 Pfizer Prod Inc Ether derivatives useful as inhibitors of phosphodiesterase type IV (PDE4) isozymes
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
CA2436551A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
EE200300360A (en) 2001-01-31 2003-12-15 Pfizer Products Inc. Biaryl derivatives of nicotinamide used as inhibitors of PDE4 isozymes
US20030175314A1 (en) * 2001-11-19 2003-09-18 Didriksen Erik Johannes Pharmaceutical composition for dermal application
US20060258703A1 (en) * 2003-07-17 2006-11-16 Ono Pharmaceutical Co., Ltd. Remedy for pruritus comprising piperidine derivative as the active ingredient
WO2005053672A1 (en) * 2003-12-04 2005-06-16 Santen Pharmaceutical Co., Ltd. Remedy for pruritus comprising cilomilast or salt thereof as the active ingredient
JP2005187458A (en) * 2003-12-04 2005-07-14 Santen Pharmaceut Co Ltd Itchiness-treating agent consisting of cilomilast or its salt as active ingredient
BRPI0507604A (en) * 2004-02-14 2007-07-03 Smithkline Beecham Corp medicines with hm74a receptor activity
JP2008137892A (en) * 2005-03-04 2008-06-19 Eisai Co Ltd Antipruritic agent
PE20070405A1 (en) 2005-08-10 2007-05-06 Smithkline Beecham Corp XANTHINE-DERIVED COMPOUNDS AS AGONISTS OF THE NICOTINIC ACID RECEPTOR HM74A
TWI404709B (en) * 2006-02-21 2013-08-11 Eisai R&D Man Co Ltd 4-(3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives
CN101389612B (en) * 2006-02-21 2011-09-21 卫材R&D管理有限公司 Quinazoline derivatives
WO2008099887A1 (en) 2007-02-16 2008-08-21 Eisai R & D Management Co., Ltd. Crystal, amorphous form and salt of methyl n-[3-(6,7-dimethoxy- 2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid
US8513269B2 (en) 2007-08-17 2013-08-20 Eisai R&D Management Co., Ltd. Preparation for external use
AU2008290000B2 (en) 2007-08-17 2012-05-10 Eisai R & D Management Co., Ltd. Method for producing quinazoline derivative
US20140121240A1 (en) * 2011-06-28 2014-05-01 Maruho Co., Ltd. Novel pharmaceutical composition
JP6678685B2 (en) 2015-01-30 2020-04-08 上海珊▲頓▼医▲薬▼科技有限公司Ｓｈａｎｔｏｎ Ｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． Prevention or treatment of uric or gouty diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563168B1 (en) * 1990-12-21 2000-07-05 Beecham Group Plc Xanthine derivatives
EP0889886B1 (en) * 1996-03-26 2002-09-18 ALTANA Pharma AG Novel phenanthridines substituted in the 6 position
EP0912568B1 (en) * 1996-05-15 2002-11-20 ALTANA Pharma AG imidazopyridines
ATE248167T1 (en) * 1997-03-07 2003-09-15 Altana Pharma Ag TETRAZOLE DERIVATIVES
EP0998300A1 (en) * 1997-03-18 2000-05-10 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
WO1998055481A1 (en) * 1997-06-03 1998-12-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridine

Also Published As

Publication number Publication date
CN1306426A (en) 2001-08-01
PL341062A1 (en) 2001-03-26
KR20010031149A (en) 2001-04-16
CZ20001376A3 (en) 2002-06-12
WO1999020280A1 (en) 1999-04-29
CO4810374A1 (en) 1999-06-30
NZ503551A (en) 2002-05-31
JP2001520196A (en) 2001-10-30
AU740875B2 (en) 2001-11-15
ZA989450B (en) 1999-04-19
BR9814080A (en) 2000-09-26
HUP0003792A2 (en) 2001-10-28
HUP0003792A3 (en) 2001-12-28
NO20001847L (en) 2000-04-10
EP1030666A1 (en) 2000-08-30
TR200001040T2 (en) 2001-01-22
CA2306985A1 (en) 1999-04-29
AU1093899A (en) 1999-05-10
IL135581A0 (en) 2001-05-20
EP1030666A4 (en) 2002-10-16
NO20001847D0 (en) 2000-04-10

Similar Documents

Publication Publication Date Title
AR015966A1 (en) USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT
MX9204268A (en) A COMPOSITION FOR THE PROLONGED AND CONTROLLED RELEASE OF MEDICINAL SUBSTANCES AND A PROCESS TO PREPARE THE SAME.
BR0108584A (en) Formulations containing an anticholinergic drug for the treatment of chronic obstructive bronchopneumopathy
ES2063073T3 (en) KNOWN AND NEW SELECTED ARYLMETHYLENE DERIVATIVES OF THIAZOLIDINONES, IMIDAZOLIDINONES AND OXAZOLIDINONES USEFUL AS ANTI-ALLERGIC AGENTS AND ANTI-INFLAMMATORY AGENTS.
ES2149264T3 (en) THERAPEUTIC AGENT FOR THE TREATMENT OF MELANOMAS.
BR0111196A (en) Compositions and use thereof for treatment of flaviviruses and pestiviruses
BR0107869A (en) Electrogenated pharmaceutical compositions
KR960013371A (en) Pharmaceutical mixture
AR034900A1 (en) USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
DK0735868T3 (en) Use of non-steroidal cyclooxygenase inhibitors for the manufacture of a medicament for the treatment of elevated intracellular
BRPI0308663B8 (en) use of IL-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
UA37259C2 (en) Active substance for pharmaceutical compositions intended for treatment of dysfunctional metrorrhagia
DE69906963D1 (en) EFAVIRENCE CONTAINING PRESSED TABLET FORMS
HUP9802971A1 (en) The use of mmp inhibitors for the treatments of ocular angiogenesis
BR0107628A (en) 1,2-diarylbenzimidazoles for treating diseases that are associated with microglial activation
BR0213293A (en) Use of tfpi or tfpi analog in the treatment of septicemia
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
CO5570661A2 (en) COMBINATIONS THAT INCLUDE COX-2 AND ASPIRINE INHIBITORS
AR023687A1 (en) A COMPOSITION FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS AND THE USE OF A GLUTAMATE ANTAGONIST FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS
BR0012169A (en) Dihydrobenzodiazepines and their use in the treatment of dyslipidemia
BR0206819A (en) Use of il-18 inhibitors for treatment and / or prevention of heart disease.
BR0209155A (en) Pharmaceutical tablet having a high api content
MXPA03010672A (en) Therapeutic compositions for repairing chondropathy.
EE200100188A (en) Optically active pyridyl-4H-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
MX9403032A (en) QUINOLYL-DIHYDROPYRIDINES, CONDENSED, PROCEDURE FOR ITS MANUFACTURE AND ITS USE IN MEDICINES.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal